Vida Ventures Advisors, LLC

In its 13F for Q1 2025 (holdings as of March 31, 2025, filed April 3, 2025), Vida Ventures Advisors, LLC reported 3 stock positions worth $13.6 million. Its top holding was Kyverna Therapeutics (KYTX) at 64.0% of the portfolio, followed by Allogene Therapeutics (ALLO, 19.3%) and Kronos Bio (KRON, 16.7%). Compared with Q4 2024, it sold out of 3. The biggest sale was an exit from Centessa Pharmaceuticals (CNTA).

Most Recent 13F
Q3 2025
Location
BOSTON, MA
CIK
0001831423
Portfolio Value
$13.6M (Q1 2025)
SEC Filing
0000950123-25-003299 ↗ filed Apr 3, 2025

Holdings Value

0$50.0M$100.0M$150.0M$200.0M Q1 2024: $180.0M Q1 2024 Q2 2024: $91.4M Q2 2024 Q3 2024: $138.6M Q3 2024 Q4 2024: $146.3M Q4 2024 Q1 2025: $13.6M $13.6M Q1 2025 Q2 2025: $15.9M Q2 2025 Q3 2025: $29.4M Q3 2025

Holdings 3 stocks · $13.6M
KYTX Kyverna Therapeutics Inc. 64.02% 4,523,924 $8.7M No change
ALLO Allogene Therapeutics Inc. 19.25% 1,798,163 $2.6M No change
KRON Kronos Bio Inc. 16.73% 2,765,314 $2.3M No change

Portfolio Sells Q4 2024 → Q1 2025
CNTA Centessa Pharmaceuticals Ltd. Sold out 0.00% −45.01
TECX Tectonic Therapeutic Inc. Sold out 0.00% −32.46
DYN Dyne Therapeutics Inc. Sold out 0.00% −6.56

Portfolio Buys Q4 2024 → Q1 2025
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q3 2025 2$29.4MKYTX, ALLO
Q2 2025 2$15.9MKYTX, ALLO
Q1 2025 3$13.6MKYTX, ALLO, KRON
Q4 2024 6$146.3MCNTA, TECX, KYTX, DYN, ALLO
Q3 2024 6$138.6MCNTA, TECX, KYTX, DYN, ALLO
Q2 2024 5$91.4MCNTA, KYTX, DYN, ALLO, KRON
Q1 2024 5$180.0MKYTX, CNTA, DYN, ALLO, KRON